Search clinical trials for: Prevention of thromboembolic events in patients with non valvular atrial fibrillation

Total 491837 results

Pfizer

Withdrawn

A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery

Pulmonary Embolism | Cerebral Stroke | Thrombosis, Deep Vein
Pfizer

Completed

S.I.F.A. II: Prevention Of Thromboembolic Events In Patients With Nonrheumatic Atrial Fibrillation (SIFA)

Atrial Fibrillation

Italy
National Research Center for Preventive Medicine
I.M. Sechenov First Moscow State Medical University; National Medical Research... and other collaborators

Completed

Non-pharmacological Prevention of Stroke in Patients With Non-valvular Atrial Fibrillation

Atrial Fibrillation

Russian Federation
AstraZeneca

Completed

Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation

Nonvalvular Atrial Fibrillation
First Affiliated Hospital Xi'an Jiaotong University
Shaanxi Provincial People's Hospital; Henan Provincial People's Hospital; 521... and other collaborators

Not yet recruiting

Response of Intracardiac Thrombus to Anticoagulants in Patients With Non-valvular Atrial Fibrillation (LYSIS) (LYSIS)

Atrial Fibrillation | Intracardiac Thrombus

China
Brian O'Neill MD
Lifetech Scientific (Shenzhen) Co., Ltd.

Not yet recruiting

Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF (CORRAL-AF)

Atrial Fibrillation | Left Atrial Appendage Thrombosis | CVA

United States
Bayer
Janssen Research & Development, LLC

Active, not recruiting

A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF) (XARIN)

Non-valvular Atrial Fibrillation (NVAF)

India
Boston Scientific Corporation

Active, not recruiting

A Pilot Study to Assess WATCHMAN FLX™ Implants by Cardiac Computed Tomography, Magnetic Resonance Imaging and Transesophageal Echocardiography: WATCHMAN FLX™ CT

The Focus of the Study is to Reduce the Risk of Stroke and Life-threatening Bleeding Events in Patients With Non-valvular Atrial Fibrillation

Denmark
Pfizer

Completed

Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation

Non-valvular Atrial Fibrillation

Japan
Bayer

Completed

An Observational Study (Called RETAF-PS) Using a Patient Survey to Learn More About Treatment Outcomes in Patients With Irregular and Often Rapid Heartbeat (Atrial Fibrillation) Treated With Apixaban in a Real World Setting

Atrial Fibrillation | Prevention of Thromboembolic Events

United States
Nippon Medical School
Daiichi Sankyo Co., Ltd.

Active, not recruiting

STroke Secondary Prevention With Catheter ABLation and EDoxaban for Patients With Non-valvular Atrial Fibrillation: STABLED Study (STABLED)

Ischemic Stroke | Atrial Fibrillation Non-Rheumatic

Japan
Bayer

Completed

A Study to Learn How the Study Treatment Asundexian Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body in Participants With Mild or Moderate Reduction of Liver Function Compared to Participants With Normal Liver Function

Atrial Fibrillation | Hepatic Impairment | Acute Myocardial Infarction | Prevention of Thromboembolic Events | Non-cardioembolic Ischemic Stroke

Germany
Bayer
Janssen Research & Development, LLC

Completed

Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation (XARENAL)

Non-valvular Atrial Fibrillation (NVAF)

Korea, Republic of
Bayer

Completed

A Study to Collect Information on the Characteristics of Elderly Belgian Patients With NVAF That Are Treated With a NOAC for This Indication With a Special Focus on Their Fear of Bleeding While Using a NOAC vs the Clinical Benefit of a NOAC of Thrombosis/Stroke Prevention. (BELANCE)

Non-Valvular Atrial Fibrillation

Belgium
Bayer
Janssen, LP

Completed

Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice (SiERRA UK)

Atrial Fibrillation

United Kingdom
Intermountain Health Care, Inc.
Boehringer Ingelheim

Completed

Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation (CAF)

Dementia | Cognition Disorders | Cerebral Ischemic Events

United States
Bayer
Janssen Research & Development, LLC

Completed

Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation (XaMINA)

Atrial Fibrillation

Korea, Republic of, Taiwan
Bayer
Janssen Scientific Affairs, LLC

Completed

Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study (XASSURE)

Stroke

China
Boehringer Ingelheim

Completed

Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)

Atrial Fibrillation

Germany
Bayer
Janssen Research & Development, LLC

Completed

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists

Atrial Fibrillation

Germany
Sejong General Hospital
Ulsan University Hospital; Korea University Anam Hospital; Yonsei University; Gachon...

Unknown

Left Atrial Appendage Occlusion Versus New Oral Anticoagulants for Stroke Prevention in Patients With Non-valvular Atrial Fibrillation

Atrial Fibrillation

Korea, Republic of
Bayer

Completed

An Observational Cross-sectional Study Evaluating the Use of Re-sources and the Sociodemographic and Clinical Characteristics of Patients Diagnosed With Non-valvular Atrial Fibrillation With a Risk of Stroke or Systemic Embolism on Anticoagulant Therapy and Treated in Primary Care Centers (BRONCE-AP)

Stroke | Atrial Fibrillation | Prevention and Control

Spain
Bristol-Myers Squibb

Completed

Clinical and Economic Burden of Bleeding Events in Patients in the UK With Non-valvular Atrial Fibrillation Treated With Vitamin k Antagonists

Atrial Fibrillation
Boehringer Ingelheim

Completed

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Atrial Fibrillation

United States, Canada
Bayer
Janssen Research & Development, LLC

Completed

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion (X-VERT)

Atrial Fibrillation

Belgium, France, Spain, China, Italy, United States, Canada, South Africa, Portugal, Singapore, Germany, Greece, Netherlands, United Kingdom, Brazil, Denmark, Finland
Bayer
Janssen R&D, L.L.C.

Completed

Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

Atrial Fibrillation

Japan
Johnson & Johnson Pharmaceutical Research & Development...
Bayer

Completed

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

Stroke | Embolism | Atrial Fibrillation

United States, Australia, France, Poland, Ukraine, United Kingdom, China, Belgium, Germany, Taiwan, Spain, Argentina, Colombia, Israel, Mexico, Bulgaria, India, Malaysia, Romania, Russian Federation, South Africa, Turkey, Korea, Republic... and more
Korea University Anam Hospital

Recruiting

Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation (REVISE-AF)

Atrial Fibrillation | Anticoagulant Adverse Reaction

Korea, Republic of
University Hospital, Caen

Not yet recruiting

SAFETY AND EFFICACY OF APIXABAN VERSUS WARFARIN IN PERITONEAL DIALYSIS PATIENTS WITH NON VALVULAR ATRIAL FIBRILLATION: A PROSPECTIVE, RANDOMISED, OPEN-LABEL, BLINDED END-POINT TRIAL (APIDP2) (APIDP2)

Atrial Fibrillation | Peritoneal Dialysis Complication
Yonsei University

Recruiting

Comparison of Patients' Satisfaction Between Dexmedetomidine and Remimazolam Anesthesia in Patients With Atrial Fibrillation Undergoing Catheter Ablation

Patients With Atrial Fibrillation Undergoing Catheter Ablation

Korea, Republic of
Daiichi Sankyo
Daiichi Sankyo Korea Co., Ltd.

Recruiting

A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation (SILVERCARE_AF)

Atrial Fibrillation

Korea, Republic of
China National Center for Cardiovascular Diseases
Chinese Academy of Medical Sciences, Fuwai Hospital

Recruiting

Population Pharmacokinetics of Edoxaban in Chinese Patients With Non-Valvular Atrial Fibrillation

Non-Valvular Atrial Fibrillation

China
Prof. Dr. med. Ingo Eitel

Recruiting

Left Atrial Appendage Closure in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic KIDNEY Disease (LAA-KIDNEY)

Non-valvular Atrial Fibrillation (NVAF): Paroxysmal, Persistent, Permanent

Germany
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

The Adherence to Oral Anticoagulant in Chinese Patients With NVAF (NVAF)

Nonvalvular Atrial Fibrillation

China
Eclipse Medical Ltd.
KCRI

Recruiting

Evaluation od Safety and Performance of the Omega™ LAA (Left Atrial Appendage) Occluder and Omega™ Delivery System in Patients With Non-Valvular Atrial Fibrillation and High Bleeding Risk (Omega)

Non-Valvular Atrial Fibrillation

Denmark, Germany, Italy, Spain, United Kingdom
University Hospital, Clermont-Ferrand

Recruiting

Study of the Effects of Anticoagulant Interruption Covered by Percutaneous Left Atrial Occlusion in Patients With Chronic Atrial Fibrillation and Radiation Cystitis at Risk of Bleeding (HEMOCC)

Radiation Cystitis | Non-valvular Atrial Fibrillation

France
Medical University of Gdansk
Institute of Cardiology, Warsaw, Poland; Medical University of Silesia; Pomeranian... and other collaborators

Recruiting

Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI (ADONIS-PCI)

Atrial Fibrillation | Acute Coronary Syndrome | Antithrombotic Therapy | Percutaneous Coronary Interventions

Poland
Yonsei University

Recruiting

Non-Interventional Study on Effectiveness of Elxaban Tab. in Patients With Non-valvular Atrial Fibrillation

Atrial Fibrillation

Korea, Republic of
Asan Medical Center
Samsung Medical Center; Pusan National University Hospital; Chonnam National... and other collaborators

Recruiting

Adding Antiplatelet During Edoxaban Treatment in Stroke Patients With Non-valvular Atrial Fibrillation (ADD-ON) ((ADD-ON))

Atrial Fibrillation | Acute Ischemic Stroke | Anticoagulant | Coronary Artery Atherosclerosis | Intracranial Atherosclerosis | Extracranial Atherosclerosis | Antiplatelet | Peripheral Artery Stenosis

Korea, Republic of
Population Health Research Institute
Hamilton Health Sciences Corporation

Recruiting

Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative AF After Noncardiac Surgery (ASPIRE-AF)

Stroke | Atrial Fibrillation

Canada, Australia, Germany, Denmark, Switzerland, Spain, Korea, Republic of, New Zealand, Argentina, India, Netherlands, United Kingdom, Brazil, Italy, Nepal, Sweden, Pakistan
Xijing Hospital
The First Affiliated Hospital with Nanjing Medical University; Peking University... and other collaborators

Not yet recruiting

Registry to Evaluate Chinese Real-World Clinical Outcomes in Patients With AF Using the WATCHMAN Left Atrial Appendage Closure Technology (RECORD)

Non-valvular Atrial Fibrillation

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4)

Non-valvular Atrial Fibrillation (NVAF) | Acute Coronary Syndrome (ACS)

China
Saint Antoine University Hospital

Recruiting

Thromboembolic and Bleeding Risk Stratification in Patients With Non-valvular Atrial Fibrillation (FASTRHAC)

Atrial Fibrillation

France
Pfizer

Completed

Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data

Non-valvular Atrial Fibrillation

Japan
Pfizer

Active, not recruiting

High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France (HELIOS-AF)

Atrial Fibrillation

United Kingdom
Bayer
Janssen Research & Development, LLC

Completed

Study to Gain Information on the Drug Xarelto for the Prevention of Brain Attack and Blockage of an Artery in the Non-central Nervous System Due to Irregular Heartbeat in Taiwanese Patients Suffering From Decreased Renal Function (XARETO)

Non-valvular Atrial Fibrillation (NVAF)

Taiwan
Bayer
Janssen Research & Development, LLC

Completed

Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban (EMIR)

Atrial Fibrillation

Spain
Bayer
Janssen, LP

Completed

Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) (REATTAIN)

Atrial Fibrillation

Sweden
Bayer

Completed

A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin (RENOVATOR)

Non-valvular Atrial Fibrillation (NVAF)

Korea, Republic of
Daiichi Sankyo, Inc.
Daiichi Sankyo (China) Holdings Co., Ltd.

Active, not recruiting

Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China (ETNA-AF-CHINA)

Non-valvular Atrial Fibrillation

China

3

Subscribe